Academic Highlights: Review of the Pharmacologic Management of Depression.[CME]
J Clin Psychiatry 2006;67(3):478-489
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Michael E. Thase, M.D., began his
presentation by stating that remission
can be defined as a virtually complete
relief of symptoms; that is, a level of
symptoms basically indistinguishable
from that of someone who has never
been depressed. In depression, remission
is usually understood to mean the
optimal level of improvement for the
acute phase treatment of an episode
of major depressive disorder. Being in
remission means that the individual
has been able to return to a normal
level of social functioning.